UH's C. T. Bauer College of Business will house the newly launched Healthcare Business Institute. Photo via Getty Images

The University of Houston announced this month that it has now launched its new Healthcare Business Institute, which will work with medical and business leaders as well as students to find solutions to pressing issues in the health care industry, such as high costs, access to care and new innovative technologies.

The institute will be part of the university's C. T. Bauer College of Business and led by Ravi Aron, research director and professor of health care strategy and technology in the Bauer College Department of Decision & Information Sciences, and Dr. Edward Kroger, the administrative director of the center.

“Providers are facing increasingly limited reimbursement from the U.S. government, insurers and employers. The industry is, therefore, struggling with finding new ways to increase value by improving quality and decreasing cost,” Aron says in a statement. “This is complicated by the fact that the industry is the most heavily regulated in the country. While policy, regulations and the government all have roles to play, efficient care delivery also requires businesses–small, medium, large and startups-to play a significant role in delivering effective and efficient care.”

The institute plans to bring together stakeholders from device makers and pharmaceutical companies to angel investors and educators to address many of these issues. Faculty and partners will release impactful research on topics such as hospital operations, new health care technologies, AI and machine learning in hospital contexts, emerging financial models in health care and a number of other topics.

Research will be shared in a new practitioner-facing Knowledge Portal that will feature a journal, editorials, and other media components like blogs, videos and audio.

The HBI will also have an educational component, with formal degree-based and shorter non-degree tracts, as well as a masters program related to health care leadership. Multiple executive education programs are also in the works.

“This unique combination of researchers, educationists and students will also benefit by connecting to perhaps the world’s most diversified health care ecosystem,” Aron says in the statement.

And Houston is the right place to house such an institute, says Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou.

“Technology, data, and AI are enabling unprecedented advances in medicine, and Houston’s impressive health care network presents an exciting opportunity for a Healthcare Business Institute,” Pavlou says in the release. “Not only is Houston home to the Texas Medical Center, UH is the only university in Houston that includes a large number of health care researchers at the Bauer College of Business, a world-ranked health law program at the UH Law Center, a computer science department with many distinguished research faculty, and a new College of Medicine."

“The opportunity for meaningful collaboration among health care researchers, industry leaders, and students through HBI will be a tremendous asset for Houston with the potential for local, national and global impact,” he continues.

Earlier this summer, UH announced plans to open a 70,000-square-foot innovation hub next to the M.D. Anderson Library on UH's main campus in 2025. It's slated to house a makerspace, the Cyvia and Melvyn Wolff Center for Entrepreneurship, the Energy Transition Institute, innovation programs, and Presidential Frontier Faculty labs and offices.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.